Thr127
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr127  -  MIG-6 (human)

Site Information
VNGVCAstPPLtPIK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 468195
Available spectra:  5 CST
Associated spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 )
Disease tissue studied:
breast cancer ( 2 ) , gastric cancer ( 10 , 11 ) , gastric carcinoma ( 10 , 11 ) , lung cancer ( 3 , 4 , 5 , 6 , 7 , 9 ) , non-small cell lung cancer ( 3 , 4 , 5 , 6 , 7 , 9 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 , 6 , 7 ) , non-small cell large cell lung carcinoma ( 4 , 6 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 15 ) , A549 (pulmonary) ( 3 ) , Cal-12T (pulmonary) ( 7 ) , Calu 6 (pulmonary) ( 9 ) , Calu-3 (pulmonary) ( 5 ) , H2009 (pulmonary) ( 9 ) , H2077 (pulmonary) ( 9 ) , H2887 (pulmonary) ( 9 ) , H322M (pulmonary) ( 9 ) , HCC1359 (pulmonary) ( 9 ) , HCC2279 (pulmonary) ( 9 ) , HCC366 (pulmonary) ( 9 ) , HCC4006 (pulmonary) ( 9 ) , HCC44 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 6 , 9 ) , HCC827 (pulmonary) ( 5 , 9 ) , HeLa (cervical) ( 1 , 12 , 13 , 14 , 16 , 17 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HMLER ('stem, breast cancer') ( 2 ) , HOP62 (pulmonary) ( 9 ) , LCLC-103H (pulmonary) ( 9 ) , lung ( 3 , 4 , 5 , 6 , 7 ) , MKN-45 (gastric) ( 10 , 11 ) , NCI-H1299 (pulmonary) ( 4 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1395 (pulmonary) ( 9 ) , NCI-H1437 (pulmonary) ( 7 ) , NCI-H1568 (pulmonary) ( 9 ) , NCI-H157 (pulmonary) ( 9 ) , NCI-H1648 (pulmonary) ( 9 ) , NCI-H1650 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 7 , 9 ) , NCI-H1703 (squamous) ( 18 , 19 , 20 , 21 ) , NCI-H1734 (pulmonary) ( 4 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1944 (pulmonary) ( 4 ) , NCI-H1975 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 9 ) , NCI-H2106 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 9 ) , NCI-H2228 (pulmonary) ( 6 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2405 (pulmonary) ( 7 ) , NCI-H3122 (pulmonary) ( 6 ) , NCI-H322 (pulmonary) ( 9 ) , NCI-H358 (pulmonary) ( 4 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H460 (pulmonary) ( 4 ) , NCI-H520 (squamous) ( 9 ) , NCI-H647 (pulmonary) ( 9 ) , NCI-H661 (pulmonary) ( 6 ) , PC9 (pulmonary) ( 9 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

9

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

10

Mulhern D (2011) CST Curation Set: 12647; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

11

Mulhern D (2011) CST Curation Set: 12863; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: T*PP Motif (T*PP) (D61C3) Rabbit mAb Cat#: 5757, PTMScan(R) T*PP Motif (T*PP) Immunoaffinity Beads Cat#: 5758
Curated Info

12

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

13

Zhou J (2010) CST Curation Set: 10691; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

14

Zhou J (2010) CST Curation Set: 10690; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

15

Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

16

Moritz A (2008) CST Curation Set: 5061; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

17

Moritz A (2008) CST Curation Set: 5070; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

18

Possemato A (2006) CST Curation Set: 1664; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

19

Possemato A (2006) CST Curation Set: 1665; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

20

Possemato A (2006) CST Curation Set: 1608; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

21

Possemato A (2006) CST Curation Set: 1570; Year: 2006; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info